

# Effects of the COVID-19 pandemic on secondary care for cardiovascular disease in the UK: an electronic health record analysis across three countries

F. Lucy Wright<sup>1</sup>, Kate Cheema<sup>2</sup>, Raph Goldacre<sup>1</sup>, Nick Hall<sup>1</sup>, Naomi Herz<sup>2</sup>, Nazrul Islam<sup>1</sup>, Zainab Karim<sup>2</sup>, David Moreno-Martos<sup>3</sup>, Daniel R Morales<sup>3,4</sup>, Daniel O'Connell<sup>2</sup>, Enti Spata<sup>1</sup>, Ashley Akbari <sup>5</sup>, Mark Ashworth<sup>6</sup>, Mark Barber<sup>7</sup>, Norman Briffa<sup>8</sup>, Dexter Canoy<sup>9</sup>, Spiros Denaxas <sup>10,11</sup>, Kamlesh Khunti<sup>12</sup>, Amanj Kurdi <sup>13</sup>, Mamas Mamas <sup>14</sup>, Rouven Priedon<sup>11</sup>, Cathie Sudlow<sup>11</sup>, Eva JA Morris<sup>1</sup>, Ben Lacey<sup>1</sup> and Amitava Banerjee <sup>10,15,\*</sup>, on behalf of the CVD-COVID-UK Consortium

<sup>1</sup>The Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK; <sup>2</sup>British Heart Foundation, London NW1 7AW, UK; <sup>3</sup>Division of Population Health and Genomics, University of Dundee, Dundee DD1 4HN, UK; <sup>4</sup>Department of Public Health, University of Southern Denmark, Odense DK-5000, Denmark; <sup>5</sup>Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Wales, Swansea, SA2 8QA, UK; <sup>6</sup>Primary Care Research Group, King's College London, London SE1 1UL, UK; <sup>7</sup>Scottish Stroke Care Audit, Public Health Scotland, Glasgow G2 6QE, UK; <sup>8</sup>Department of Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK; <sup>9</sup>Population Health Sciences Institute, University of Newcastle, Newcastle NE2 4AX, UK; <sup>10</sup>Institute of Health Informatics, University College London, London NW1 2DA, UK; <sup>11</sup>British Heart Foundation Data Science Centre, Health Data Research UK, London NW1 2BE, UK; <sup>12</sup>Leicester Diabetes Centre, University of Leicester, Leicester LE5 4PW, UK; <sup>13</sup>Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow G4 ORE, UK; <sup>14</sup>Keele Cardiovascular Research Group, Keele University, Stoke on Trent ST5 5BG, UK; and <sup>15</sup>Department of Cardiology, Barts Health NHS Trust, London E1 1BB, UK

Received 4 November 2022; revised 9 November 2022; accepted 14 November 2022; online publish-ahead-of-print 16 November 2022

Background	Although morbidity and mortality from COVID-19 have been widely reported, the indirect effects of the pandemic beyond 2020 on other major diseases and health service activity have not been well described.
Methods and results	Analyses used national administrative electronic hospital records in England, Scotland, and Wales for 2016–21. Admissions and procedures during the pandemic (2020–21) related to six major cardiovascular conditions [acute coronary syndrome (ACS), heart failure (HF), stroke/transient ischaemic attack (TIA), peripheral arterial disease (PAD), aortic aneurysm (AA), and venous thromboembolism(VTE)] were compared with the annual average in the pre-pandemic period (2016–19). Differences were assessed by time period and urgency of care. In 2020, there were 31 064 (-6%) fewer hospital admissions [14 506 (-4%) fewer emergencies, 16 560 (-23%) fewer elective admissions] compared with 2016–19 for the six major cardiovascular diseases (CVDs) combined. The proportional reduction in admissions was similar in all three countries. Overall, hospital admissions returned to pre-pandemic levels in 2021. Elective admissions remained substantially below expected levels for almost all conditions in all three countries [-10 996 (-15%) fewer admissions]. However, these reductions were offset by higher than expected total emergency admissions [+25 878 (+6%) higher admissions], notably for HF and stroke in England, and for VTE in all three countries. Analyses for procedures showed similar temporal variations to admissions.
Conclusion	The present study highlights increasing emergency cardiovascular admissions during the pandemic, in the context of a substantial and sustained reduction in elective admissions and procedures. This is likely to increase further the demands on cardiovascular services over the coming years.

\* Corresponding author: Tel: +02035495449, Fax: +02076798002, Email: ami.banerjee@ucl.ac.uk

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Graphical Abstract Monthly total admissions for CVD as primary diagnosis across subtypes, across three countries in the UK and across pre-pandemic (2016–2019) and pandemic (2020–2021) periods.

Key question: What is the impact in 2020 and 2021 of the COVID-19 pandemic on hospital admissions and procedures for six major CVDs in England, Scotland, and Wales?



## Keywords

Key finding: In 2020, there were 6% fewer hospital admissions (emergency: -4%, elective: -23%) compared with 2016-19 for six major CVDs, across three UK countries. Overall, admissions returned to pre-pandemic levels in 2021, but elective admissions remained below expected levels. Take-home message: There were increasing emergency cardiovascular admissions during the pandemic, with substantial and sustained reduction in elective admissions and procedures. This is likely to increase further the demands on cardiovascular services over the coming years.

# Introduction

Since the early stages of the coronavirus (COVID-19) pandemic, acute workload on health systems managing those with the virus has led to direct effects (e.g. hospitalisations, intensive care admissions, and mortality of infected individuals).<sup>1–3</sup> In addition, indirect effects have impacted non-COVID diseases by health system strain and changes in behaviours, documented across some individual specialties, clinical procedures, and countries but only in the first year of the pandemic.<sup>4–7</sup>

The role of non-communicable diseases (NCDs) and their care as a COVID-related risk factor and outcome is consistent with a 'syndemic'—'characterised by biological and social interactions between conditions and states, interactions that increase a person's susceptibility to harm or worsen health outcomes'.<sup>8</sup> However, pandemic planning and preparedness excludes modelling of indirect effects, which have not been of this scale in prior public health emergencies. Moreover, pandemic monitoring has focused on metrics of infection, excluding NCDs as a risk factor or indirect outcome.<sup>9</sup>

Cardiovascular disease (CVD) is the greatest burden of disease in UK and globally.<sup>10</sup> Any attempt to quantify indirect effects or NCDs must consider CVD. Even in the early first wave, there were indirect effects across six CVD subtypes in nine UK hospitals with reduced admissions, emergency department attendances and procedures after lockdown (23 March 2020) by 58, 53, 31, and -88% respectively, compared with prior years.<sup>2</sup> Several studies confirmed indirect effects in different CVD subtypes and countries.<sup>7,11–13</sup> However, over 2 years into the pandemic with increasing non-COVID care backlogs in the UK and other countries, three questions remain. First, 'was the risk profile of individuals with CVD different before and during

COVID-19?', which could inform risk prediction models and CVD prevention priorities during pandemics. Second, 'How has clinical activity varied across subtypes<sup>14</sup>, admissions and procedures during the pandemic?', to understand impact of changing pandemic waves and policy landscapes, including vaccinations and lockdowns. Third, 'Are CVD admissions and procedures affected more for elective or emergency activity?', to inform service planning and resource utilisation during and post-COVID-19. In the CVD-COVID-UK/COVID-IMPACT consortium, national electronic health record (EHR) data are available for pandemic-related research.<sup>15,16</sup>

# **Objectives**

Using EHR phenotypes for CVD and associated procedures,<sup>14</sup> the indirect impact of the COVID pandemic on CVD can be studied with access to data for 65.7 million individuals across multiple sources with > 700 validated phenotyping algorithms. For six major CVD subtypes [acute coronary syndrome (ACS), heart failure (HF), stroke/transient ischaemic attack (TIA), peripheral arterial disease (PAD), aortic aneurysm (AA), and venous thromboembolism (VTE)] in three UK countries (England, Scotland, and Wales), we investigated hospital activity before (2016–19) and during the COVID-19 pandemic (2020–21) by: (i) demographic characteristics; (ii) admissions and procedures; and (iii) urgency of care.

# Methods

## Setting and data sources

National administrative hospital records for England, Scotland, and Wales were used for this study and data sources are shown in supplementary material online, *Figure S1*. Data were accessed through each country's trusted research environment (TRE), which was made possible through agreements with Health Data Research UK for the British Heart Foundation Data Science Centre's CVD-COVID-UK/COVID-IMPACT research programme.<sup>15,16</sup> For England, data were obtained from the Admitted Patient Care Hospital Episode Statistics in NHS Digital's TRE service for England. For Scotland, the Scottish Morbidity Records (SMR 01) for General/Acute Inpatient and Day Case admission in the Scottish National Safe Haven was the data source<sup>17</sup> and for Wales, it was the Patient Episode Database Wales in the Secure Anonymised Information Linkage (SAIL) Databank.<sup>18</sup> These datasets cover inpatient admissions to all NHS hospitals including day cases.

379

Downloaded from https://academic.oup.com/ehjqcco/article/9/4/377/6831631 by guest on 01 March 2024

Data extraction and analysis of patient-level hospital data was undertaken in each nation's TRE using common data specifications and analysis codes, accounting for differences in data structure and clinical coding procedures between the three nations. In the raw form, each record represents a new admission, a change between medical specialists within the same admission or an inter-hospital transfer. To minimise over-counting, a record that represented a continuous hospital stay and included changes between medical specialists within the same admission and accounted for inter-hospital transfers was created. Only aggregated data were shared.

# **Study population**

The study population included all individuals admitted to hospital in England, Scotland, or Wales with a primary diagnosis of each CVD subtype between 1 January, 2016 and 31 December, 2021- the study period covers 4 years before the COVID-19 pandemic for comparison with the first 2 years of the pandemic. The study population also included all individuals admitted for each of the associated CVD procedures to ensure that all procedures were captured, since the associated CVD subtype diagnosis might not necessarily be recorded as the primary diagnosis for these admissions.

# Admissions for cardiovascular diseases diagnoses and procedures

Included CVD diagnoses were ACS, HF, stroke/TIA, PAD, AA, and VTE. Associated CVD procedures were percutaneous coronary intervention, coronary artery bypass graft surgery, pacemaker/cardiac resynchronisation therapy, ventricular assist device/heart transplant, stroke thrombolysis/thrombectomy, carotid endarterectomy/stenting, cerebral aneurysm coiling, AA repair, peripheral limb angioplasty, limb revascularisation, bypass/amputation, and pulmonary artery embolectomy/ embolisation.

Phenotypes for CVD diagnoses were defined using the international classification of diseases, 10th revision (ICD-10 codes) and procedures using office of population censuses and surveys classification of interventions and procedures, version 4 (OPCS-4 codes). These were chosen to align with an earlier study<sup>2</sup> and a few minor modifications were made to OPCS-4 codes after clinical and academic expert consensus (e.g. additional codes for coronary artery bypass surgery or pacemaker insertion). For procedures, we counted all recorded procedures in a single admission. Details of diagnostic and procedural clinical terminology codes are in supplementary material online, *Table S1*.

Admissions, not individuals, were counted. One patient may have been readmitted for a CVD subtype or procedure, or had an admission for other CVD subtypes or procedures during the study period, and each admission was counted. Admissions were classified as emergency or elective using the admission type variable in each dataset. Generally, emergency admissions were, when the admission was unpredictable and at short notice due to clinical need, such as referrals from accident and emergency, a general practitioner, or a clinic. Admissions were classified as elective when the decision to admit could be separated from the time of the actual admission such as being admitted from a waiting list, or having the admission booked or planned at the time when it was deemed clinically necessary.

#### Statistical analysis

Analyses were for men and women combined and for all ages. Demographic characteristics of individuals admitted to hospital pre-pandemic and those admitted during the first 2 years of the pandemic for CVD subtypes and procedures were investigated. The characteristics were for each admission and included sex, age, and ethnic group, and Charlson comorbidity index using ICD-10 codes from the admission.<sup>19</sup> The average number of people in each category of the selected demographic characteristic was divided by the average number of admissions. Due to small numbers (<5) in some categories, characteristics for 2020 and 2021 were reported as an average of the 2 years. For all other analyses, 2020 and 2021 are reported separately. The average of 2016–19 was selected as the comparator for all analyses, using a four-year period to give stability over time.

Initially all admissions (emergency and elective combined) were assessed. To explore indirect effects of the pandemic on unplanned and planned CVD care and inform policy responses, admissions were reported separately as emergency or elective, respectively. Annual counts were calculated within the three time periods of interest: pre-pandemic 2016–19, and pandemic 2020 and 2021. The percentage change between time periods was calculated by subtracting the total for each pandemic year from the 2016–19 average and dividing by the 2016–19 average. Percentage changes were calculated with 95% confidence intervals, assuming pre-pandemic annual counts followed a negative binomial distribution. Monthly counts of admissions were also calculated and plotted to show trends during the years. The analyses were performed according to a pre-specified protocol and analysis plan with phenotyping and analysis code, which is available at https://github.com/BHFDSC/CCU003\_04.

# **Results**

## **Study population**

We identified a total of 1 973 104 and 970 374 admissions and 16 16 550 and 635 187 procedures in 2016–19 and 2020–21 respectively.

# **Demographic characteristics**


There were no major differences by age, gender, or ethnic group between 2016–19 and 2020–21 for admissions (Supplementary material online, *Table S2*) or procedures (Supplementary material online, *Table S3*) across countries, or CVD subtypes. The Charlson comorbidity profile was more severe in 2020–21, compared to 2016–19, for all admissions and all procedures in England, except ventricular assist device)/transplant and PA embolectomy. In Scotland, individuals with PAD (20.4 vs. 17.9%) and VTE (18.8 vs. 17.9%) had more severe comorbidities in 2020–21, compared with pre-pandemic, but otherwise, in Scotland and Wales, there were no notable differences by comorbidities in admissions or procedures between pre- and post-pandemic periods.

# **Hospital admissions**

#### **Total admissions**

In 2020, there were 31 064 (-6%) fewer admissions for all six CVD subtypes combined in the three countries overall, compared with the expected 2016–19 numbers. In 2021, there was an overall increase of 14 884 (+3%) admissions. Figure 1 shows annual counts and percentage change in total admissions for CVD as the primary diagnosis for all CVD and across subtypes for each country. In 2020, admissions for all CVD in the three individual countries were lower than expected (-6% in England, -6% in Scotland, and -7% in Wales). In 2021, admissions in England were 4% higher than expected, but in Scotland and Wales, numbers were similar to 2016–19.

For most CVD subtypes, admissions in 2020 were lower than expected across countries compared with 2016–19 (Figure 1). Admissions for ACS, AA, and PAD were lower in all three countries (annual % change range: -6 to -27%), and for HF in Wales (-13%). For stroke/TIA in England, admission numbers were somewhat lower (-3%). For the remaining CVD subtypes, the observed numbers of admissions in 2020 were similar to those in 2016–19. In 2021 in all three countries, admissions for AA and PAD continued to remain lower than expected (range: -10% AA in Scotland to -19% AA in Wales) and there were more admissions for VTE than expected (range: +11% in Scotland to +27% in Wales). In England, there



PCI= Percutaneous Caronary Intervention, CABG= Coronary Artery Bypass Graft, PPM= Permanent Pacemaker Implantation, VAD= Ventricular Assist Device, AA= Aortic Aneurysm, VTE= Venous Thromboembolism, PA = Pulmonary Artery


**Figure 1.** Annual counts and percentage change in total admissions and procedures between pre-pandemic (2016–19) and pandemic (2020–21) periods for cardiovascular disease as primary diagnosis for all cardiovascular disease and across subtypes and across three countries in the UK.

were somewhat more admissions for stroke/TIA in England (+4%). In Scotland, admissions for ACS, HF, and stroke/TIA were similar in 2021 compared to 2016–19. In Wales, admissions for ACS and stroke/TIA were lower, -5 and -7% respectively.

The observed changes were not uniform throughout the two pandemic years (Graphical abstract). In 2020, monthly admissions for all CVD subtypes in all three countries decreased from January, with greatest reductions in April, compared to 2016–19. Admissions remained lower than expected during the rest of 2020, except VTE admissions which increased above 2016–19 levels by May/June 2020 and throughout 2021. In 2021, monthly admissions for all CVD subtypes were lower than 2016–19 levels in January and February in all three countries, except VTE. Timing and extent of recovery to expected levels varied by CVD subtype and country.

#### Urgency of care

In 2020, there were 14 506 (-4%) fewer emergency admissions than expected for all CVD in the three countries combined, and the proportion reduction was similar in all three countries. For most CVD subtypes, emergency admissions in all three countries were similar to those in 2016–19 (Figure 2). The exceptions were ACS in England (-8%), HF in Wales (-13%), stroke/TIA in England (-3%), AA in England and Scotland (-9 and -12% respectively), and PAD in England (-5%). There were also fewer elective admissions for all CVD in 2020 with a total of 16 560 (-23%) for Scotland). For most CVD subtypes across countries compared with 2016–19, elective admissions were lower (e.g. -16% ACS in England and stroke/TIA in Scotland, -35% HF in Scotland). Admissions with the greatest reductions were AA



**Figure 2.** Annual counts and percentage change in total emergency and elective admissions between pre-pandemic (2016–19) and pandemic (2020–21) periods for cardiovascular disease as primary diagnosis for all cardiovascular disease and across subtypes and across three countries in the UK.

(-34, -38, and -37%) and PAD (-30, -36, and -40%) in England, Scotland, and Wales respectively. Admission numbers were similar to 2016–19 for ACS in Scotland and Wales, Stroke/TIA in England and Wales and VTE in England and Scotland. No admissions for CVD subtypes were higher than expected.

In 2021, there were 25 878 (+6%) more emergency CVD admissions in the three countries combined. This was driven by the 7% higher number of admissions in England, while in Scotland and Wales numbers returned to expected levels (Figure 2). For most CVD subtypes across countries, the number of emergency admissions returned to expected levels, although there were some exceptions. Admissions were higher than expected in all three countries for VTE (England +19%, Scotland +29%, and Wales +13%). In England, admissions were higher than expected for HF (+11%), stroke/TIA (+5%), and PAD (+6%) and somewhat lower for AA (-4%). Elective admissions remained lower in 2021 with 10 996 (-15%) fewer CVD admissions than in 2016–19 in the three countries combined (England -14%, Scotland -25%, and Wales -15%). For individual CVD subtypes, elective admissions remained below pre-pandemic levels across all subtypes and countries, except HF in Wales (+23%) (Figure 2). Monthly emergency and elective admissions across CVD subtypes and across countries decreased between January and April 2020 (Figures 3 and 4 respectively). Emergency activity returned to 2016-19 levels by June/July 2020, except for VTE which remained higher throughout the rest of 2020 and 2021. Between February and April 2021, emergency CVD admissions exceeded 2016-19 levels,


then decreased, particularly in Wales, where ACS, HF, and stroke admissions decreased to lower than pre-pandemic levels (Figure 3). Other than VTE, elective admissions did not return to expected levels by end of 2021, across CVD subtypes and countries (Figure 4). Reductions for elective and emergency admissions were greater in England and Wales.


# Procedures

#### Total procedures

In 2020, there were 96 554 (-24%) fewer total procedures for all six CVD subtypes combined in the three UK countries compared with the expected number in 2016–19. In 2021, there were 76 541 (-19%) fewer CVD procedures. In 2020, admissions for all CVD procedures in the three individual countries were lower than expected and varied by country (England -25%, Scotland -16%, Wales -23%) (Figure 1). In 2021, there was a small increase (5–8%) in all CVD procedures in the three countries, but numbers remained below expected levels (England -20\%, Scotland -10%, and Wales -15%).

There were major reductions across most individual CVD procedures in 2020 compared to 2016–19. These included percutaneous coronary intervention (range: -17% in Scotland to -27% in England), coronary artery bypass graft surgery (-23% in Scotland to -44% in Wales), carotid endarterectomy (England -24% to Wales -43%) and limb angioplasty (-16% in England to -30% in Wales). Only





stroke thrombolysis in England was higher than expected (+8%), and cerebral artery coiling in all three countries was similar to 2016–19. In 2021, although there was some improvement, most CVD procedures remained well below the expected levels in all three countries, ranging from -6% for PAD re-vascularisation in Scotland to -49% for carotid endarterectomy in Wales. Only stroke thrombolysis in England (+17%), cerebral artery coiling in Scotland (+21%), and ventricular assist device or heart transplant in Scotland (+81%) were higher, but numbers were low and confidence intervals wide. Generally, monthly numbers of CVD procedures were lower in 2020 and 2021, compared to 2016–19 across countries (Figure 5).

Observed changes were not consistent throughout 2020 and 2021 (Figure 5). In 2020, monthly admissions for all CVD procedures in all three countries decreased from January, with greatest reductions in April, compared to 2016–19. Overall admissions for procedures all CVD subtypes remained lower than expected during the rest of 2020 and 2021 in all three countries.

#### Urgency of care

In 2020 there were 11 775 (-9%) fewer emergency CVD procedures than in 2016–19 in all three countries combined. The proportion change varied between countries (England -10%, Scotland +3%, and Wales -4%) (Figure 6). The total number of individual emergency CVD procedures was either lower than or similar to 2016–19. Examples of procedures that were lower were coronary artery bypass graft surgery (-26% in England, -57% in Wales), carotid endarterectomy

(-36% in Wales), AA repair (-23% in England and -25% in Wales) and pulmonary artery embolectomy (-20% in England). Some procedures were higher in 2020 than expected: permanent pacemaker or resynchronisation therapy in Scotland (+20%) and cerebral artery coiling (+15% in England and +47% in Wales), although numbers were relatively low.

In 2021 there were only 1990 (-2%) fewer emergency CVD procedures in all three countries combined, with some variation observed between countries (England -2%, Scotland +10%, and Wales 0%). Generally, there was variability across individual CVD procedures and countries (Figure 6). For example, emergency coronary artery bypass graft surgery was lower in England (-9%) and Wales (-53%) and higher in Scotland (+46%). However, AA repair across all three countries remained lower in 2021 than in 2016–19 (England -19%, Scotland -18%, and Wales -33%).

For elective CVD procedures in 2020, there were 84 766 (-31%) fewer procedures combined for all three countries (England and Wales -32%, Scotland -21%). Individual elective procedures were all lower in 2020 compared to 2016–19 across countries, except stroke thrombolysis was higher in England (+230%, N +81). The reduction in CVD procedures varied by country and procedure, e.g. -39, -39, and -24% for CABG, and -29, -24, and -41% for limb angioplasty in England, Wales, and Scotland, respectively.

In 2021, the reduction in elective procedures persisted with 74 566 (-27%) fewer elective CVD procedures combined for all three countries (England -29%, Scotland -15%, and Wales -23%) (Figure 6).




Figure 4. Monthly elective hospital admissions for cardiovascular disease as primary diagnosis across subtypes, across three countries in the UK and across pre-pandemic (2016–19) and pandemic (2020–21) periods.

The reductions continued for all individual elective procedures, except stroke thrombolysis in England. Between January and April 2020, monthly emergency procedures decreased for AA, ACS, HF, and PAD, recovering to pre-pandemic levels in late 2020 and 2021. (Supplementary material online, *Figure S2*). Monthly elective procedures decreased in January to April 2020, across subtypes and countries, and had not recovered to 2016–19 levels by end of 2021 (Supplementary material online, *Figure S3*).

# Discussion

In the first comprehensive study to use national routinely collected electronic hospital data in the pandemic context across CVD subtypes, admissions, procedures, urgency of care, and countries, we demonstrate three major findings. First, there were profound reductions across CVD subtypes and countries during the pandemic, particularly for procedural activity which reduced by a third in 2020 and by a quarter in 2021, compared with pre-pandemic levels. Second, except for VTE, although emergency admissions and procedures had returned to pre-pandemic levels by 2021, elective activity remained significantly reduced, especially for procedures. Third, the comorbidity profile for CVD admissions and procedures was more severe during the pandemic than pre-pandemic in England for most CVD subtypes but did not generally differ between 2020–21 and 2016–19 for Scotland and Wales. Despite multiple analyses of indirect effects in the UK and other countries using EHR, <sup>11–14,20</sup> these effects have been neglected in pandemic surveillance and policy responses.<sup>21</sup> Moreover, prior analyses have tended to be disease- or procedure-specific and have not taken a system-level view across diseases and countries.<sup>22</sup> We now confirm previous reports of reduced activity for admissions and for PCI and other CVD-related procedures, showing variation by timing, speed, and extent of recovery across subtypes. Given the significant backlogs across services in the UK<sup>23–25</sup> and other countries,<sup>26</sup> there is an urgent need to monitor and understand these indirect impacts of the COVID-19 pandemic, to develop coordinated, but tailored responses, based on subtype, type and urgency of care, and country. Without urgent action, indirect and long-term consequences could create far greater burden and cost to individuals, populations, and health systems than acute, direct effects.

Reductions in emergency care are likely to require different approaches to workforce and resource planning, compared with elective care, and for admissions vs. procedures.<sup>27,28</sup> Therefore, the greater effect on procedural activity and the relatively slower recovery of elective procedural activity, especially in England and Wales, requires further investigation, explanation, and mitigation strategies. The widespread strain on health systems due to COVID-19 is unprecedented and staff and resource shortages over successive waves may provide part of the explanation. In 2021, some emergency admissions were greater than pre-pandemic levels, which may in part, be related to the reduction in elective admissions and procedures the year




Figure 5. Monthly total procedures for cardiovascular disease across subtypes, across three countries in the UK and across pre-pandemic (2016–19) and pandemic (2020–21) periods.

before. There may also have been changes in coding of admissions as 'emergency' or 'urgent' so that they were less delayed during the pandemic.

Although projections from national and international efforts such as the Global Burden of Disease Study provide important context,<sup>29</sup> more detailed national-and local-level data regarding CVD re-admissions, and non-COVID and CVD deaths are required for informed health policy. Ultimately, answers require standardised, near real-time data which has become possible in the COVID-19 context but has historically not been a priority. To-date, admissions and procedures have been tracked in a 'rear view mirror', which is not fit-for-purpose for surveillance and planning during public health emergencies such as pandemics, due partly to specialty- and disease-specific silos, and partly due to a culture of retrospective data collection, monitoring, and analysis. For example, the UK's National Heart Failure Audit and National Audit of PCI publish annual reports with a one year delay, which has been further delayed or de-prioritised during the pandemic<sup>30</sup> and national AA screening data during the pandemic has not been published.<sup>31</sup> National EHR data can and should be used to study CVD and non-COVID diseases and services at scale, with low-hanging fruits for public health and policy planning during and post-pandemic.

Late presentation, greater severity of illness, and inequalities in access to healthcare have been invoked to explain increased rates of CVD during the pandemic. The finding of similar baseline char-

acteristics before and during the pandemic among most individuals presenting with CVD and undergoing CVD-related procedures in Scotland and Wales suggests that these patient-level factors (including age, sex, and ethnicity) do not fully explain the reductions in CVD care during the pandemic, and that system-level factors may be more important. However, for most CVD subtypes in England, there was greater comorbidity burden in those presenting during pandemic years than during pre-pandemic years, which could suggest decreased prevention, late presentation, and/or reduced access to CVD services. We show differences by subtype, by urgency of care, and by country, which may signify different reasons for reductions in activity and therefore different, nuanced solutions. For example, the higher impact on CABG, carotid endarterectomy, and PAD procedures needs to be explored. There is now clear evidence of increased VTE risk associated with COVID-19, up to 1 year after infection, which at least partly explains the observed increase in VTE admissions and procedures.<sup>32</sup> We have only considered certain CVD admissions and procedures, but indirect effects across all diseases and procedures are likely. A complex interplay of factors makes analysis difficult with successive pandemic waves, lockdowns, vaccination programmes, and changing COVID-19-related policies. However, without a whole-system perspective and better up-to-date data, the indirect effect across diseases cannot be quantified, tackled, or predicted. Only then can the correct, nuanced approaches to workforce, public health priorities, and health resource utilisation be planned.

redure for.	Mean No. 2016/19	Total No. 2020	Difference 2016/19 to 2020		% change (95% Cl) 2016/19 to 2020	Total No. 2021	Difference 2016/19 to 2021		% change (95) 2016/19 to 2
ergency Proced procedures	ures								
England	114799 6764	103164	-11635 188	•	-10 (-11,-9)	112179 7421	-2620 657	•	-2 (-3,-1)
Scotland Wales	7321	6952 6993	-328	•	3 (0,6) -4 (-8,0)	7421 7294	-27		10 (7,13) 0 (-4,4)
lac									
England Scotland	68542 4280	60891 4317	-7651 37	•	-11 (-13,-9) 1 (-3,5)	65105 4564	-3437 284		-5 (-7,-3) 7 (3,11)
Vales	3651	3794	143	•	4 (0,8)	4092	441		12 (8,16)
ingland	3786	2789	-997		-26 (-29,-23)	3459	-327		-9 (-12,-5
cotland	75	71	-4	·•	-5 (-29,27)	109	34	· · · · · ·	46 (15,86)
Vales Failure	277	118	-159		-57 (-65,-48)	129	-148		-53 (-61,-4
resynchronis ngland	ation 21011	19387	-1624		-8 (-12,-3)	21777	766		4 (-2,9)
cotland	573	688	115		20 (8,33)	807	234		41 (28,55
Vales transplant	1581	1345	-236	H•4	-15 (-24,-5)	1457	-124	<b>1</b> − <b>0</b> in	-8 (-17,3)
ngland cotland	106	63 6	-43	·•	-41 (-54,-23)	57	-49		-46 (-59,-2
/ales		0							
e/TIA nbolysis or th	rombectomy								
ngland cotland	3828	4049	221	-	6 (0,12)	4400	572		15 (8,22) 0 (0.0)
/ales	243	261	18		8 (-20,45)	244	1		0 (0,0) 1 (-25,35
id endartecto ngland	my or stenting 901	840	-61		-7 (-13,1)	888	-13		-1 (-8,6)
cotland	40	45	5		14 (-18,59)	40	0	·	1 (-28,43
/ales g of cerebral	84 artery	54	-30		-36 (-56,-5)	63	-21		-25 (-48,5
ngland cotland	775	894	119		15 (1,31)	863	88		11 (-2,27
/ales	111 45	100 66	-11 21	•	-10 (-27,12) 47 (4,110)	145 46	34 1		31 (8,58 3 (-31,53
vascular									
ngland	2702	2077	-625		-23 (-35,-10)	2176	-526		-19 (-31,-
cotland /ales	244 199	209 149	-35 -50		-14 (-27,1) -25 (-41,-5)	200 134	-44 -65		-18 (-31,- -33 (-47,-1
angioplasty									
ngland	5991	5504	-487	H <b>H</b> H	-8 (-13,-3)	6126	135	+	2 (-3,8)
cotland Vales	499 417	535 359	36 -58		7 (-7,23) -14 (-27,2)	534 339	35 -78		7 (-7,23) -19 (-31,-1
cularisation,	bypass or amput	ation							
ngland cotland	7024 904	6563 958	-461 54	•	-7 (-10,-3) 6 (-1,14)	7185 1005	161 101		2 (-1,6) 11 (4,19
/ales	814	841	27		3 (-7,15)	774	-40		-5 (-15,6)
bolectomy									
ngland	133	107	-26		-19 (-35,-1)	143	10 -21		8 (-10,30 -55 (-88,6
cotland Vales	38 10 Mean No.	23 6	-15 -4 Difference	-50 0 50 100	-39 (-83,112) -38 (-74,45) 130 % change (95% Ci)	17 16	6 Difference	150 400 -50 0 50 100 150	→ 64 (-8,194 200 250 % change (95
cotland Vales dure for. ve Procedure ocedures	10 Mean No. 2016/19	6 Total No. 2020	-4 -100 Difference 2016/19 to 2020	-30 0 50 100	-38 (-74,45) 150	16 Total No. 2021	6 Difference 2016/19 to 2021		→ 64 (-8,194 200 250 % change (95
dure for. we Procedures ngland	10 Mean No. 2016/19 5 237554	6 Total No. 2020 162283	-4 -100 Difference 2016/19 to 2020 -75271		-38 (-74,45) 150 % change (95% CI) 2014/19 to 2020 -32 (-38,-25)	16 Total No. 2021 169747	6 Difference 2016/19 to 2021 -67807	130 -336 -36 0 50 100 150 ⊷⊷⊷	→ 64 {-8,194 200 230 % change (95 2016/19 to 3 -29 (-35,-2
dure for. ve Procedure ocedures ingland cotland Vales	10 Mean No. 2016/19	6 Total No. 2020	-4 -100 Difference 2016/19 to 2020		-38 (-74,45) 150 % change (95% Cl) 2016/19 to 2020	16 Total No. 2021	6 Difference 2016/19 to 2021		→ 64 (-8,194 200 250 % change (95 2016/19 to 2 -29 (-35,-2 -15 (-17,-1
dure for. we Procedure ocedures ngland cotland Vales	10 Mean No. 2016/19 237554 24235	6 Total No. 2020 162283 19105	-4 Difference 2016/19 to 2020 -75271 -5130		-38 (-74,45) 150 % change (95% Cl) 2016/18 to 2020 -32 (-38,-25) -21 (-22,-20)	16 Total No. 2021 169747 20530	6 Difference 2016/19 to 2021 -67807 -3705		→ 64 (-8,194 200 230 % change (95 2016/19 to 2 -29 (-35,-2 -15 (-17,-1
dure for. ve Procedures ingland cotiand cotiand cotiand cotiand	10 Mean No. 2016/19 237554 24235 13455 128388	6 Total No. 2020 162283 19105 9090 82479	-4 -100 Difference 2016/19 to 2020 -75271 -5130 -4365 -45909		-38 (-74,45) 255 <b>% change (95% Cl)</b> <b>2016/19 to 2020</b> -32 (-38,-25) -32 (-38,-26) -36 (-43,-28)	16 Total No. 2021 169747 20530 10401 88097	6 Difference 2016/19 to 2021 -67807 -3705 -3054 -40291		→ 64 (8,194 205 250 % change (95 2016/19 to 3 -29 (-35,-2 -15 (-17,-1 -23 (-29,-1 -31 (-39,-2
dure for. we Procedure condures ngland cotland vales te mgland cotland	10 Mean No. 2016/19 237554 24235 13455	6 Total No. 2020 162283 19105 9090	-4 Difference 2016/19 to 2020 -75271 -5130 -4365		-38 (-74,45) 350 % change (95% CL) 2016/19 to 2020 -32 (-38, -25) -32 (-38, -28)	16 Total No. 2021 169747 20530 10401	6 Difference 2016/19 to 2021 -67807 -3705 -3054		→ 64 (8,194 200 230 % change (95 2016/19 to 2 -29 (-15, 2 -15 (-17, -1 -23 (-29, -1 -23 (-29, -1 -31 (-19, -2 -16 (-18, -1)
dure for. vales dure for. ve Procedure ocedures ngland cotland vales ac ngland cotland Vales	10 Mean No. 2016/19 237554 24235 13455 128388 14369 7502	6 Total No. 2020 162283 19105 9090 82479 11122 4802	-4 -100 Difference 2016/19 to 2020 -75271 -5130 -4365 -45909 -3247 -2700		-38 (74,45) 150 <b>% change (95% CI)</b> <b>2016/19 to 2020</b> -12 (-38,-25) -21 (-22,-20) -32 (-38,-25) -32 (-38,-25) -36 (-41,-22) -36 (-41,-22)	16 Total No. 2021 169747 20530 10401 88097 12017 5569	6 Difference 2016/19 to 2021 -67807 -3054 -3054 -40291 -2352 -1933		→ 64 (4,39 200 200 200 2015(7)9 to 2 2015(7)9 to 2 2015(7)9 to 2 2015(7)9 to 2 2015(7)7 2015
dure for. vales dure for. ve Procedures ngland cotland vales te ngland cotland vales ngland cotland vales	10 Mean No. 2016/19 237554 24235 128388 14369 7502 11765 1223	6 Total No. 2020 162283 19105 9090 82479 11122 4802 7172 941	-4 .10 Difference 2016/19 to 2020 -75271 -5120 -4365 -45909 -3247 -2200 -4593 -294		-38 (74,45) 150 <b>% change (95% CI)</b> <b>2016/19 to 2020</b> -12 (38,25) -21 (42,28) -32 (43,28) -36 (43,28)	16 Total No. 2021 169747 2030 10401 88097 12017 5569 7722 953	6 Difference 2016/19 to 2021 -67807 -3705 -3054 -40791 -2352 -1933 -4043 -282		→ 66 ( ₹.).9 200 200 30 2016/19 to 2 2016/19 to 2 201
dure for. e Procedure scedures sc	10 Mean No. 2016/19 237554 24235 13455 128388 14369 7502 11765	6 Total No. 2020 162283 19105 9090 82479 11122 4802 7172	-4 -100 Difference 2016/19 2020 -75271 -5130 -4365 -4365 -4365 -4369 -3247 -2700 -4593		-38 (74,45) 50 50 50 50 50 50 50 50 50 50	16 Total No. 2021 169747 20530 10401 88097 12017 5569 7722	6 Difference 2016/19 to 2021 -67807 -3705 -3054 -40291 -40291 -2352 -1933 -4043		→ 66 (8,19 200 200 2016/29 to: 2016/29 t
dure for. raies dure for. re Procedure redures reland roland raies reland roland raies reland roland raies reland roland raies Failure Failure	10 Mean No. 2016/19 237554 24215 134555 128388 14360 7502 11765 742 ation	6 Total No. 2020 162283 19105 9090 82479 11122 4802 7172 941 450	-4 2014/19 to 2020 -75373 -130 -4365 -4365 -45909 -3247 -2200 -4593 -294 -292		-38 (-74,45) 10 % change (95% Cl) 2016(15 to 2020 -32 (-38,25) -32 (-38,25) -32 (-38,26) -36 (-41,28) -36 (-41,21) -36 (-41,21) -36 (-41,21) -36 (-43,31) -36 (-43,32) -36 (-43,33) -36 (-43 (-43,33) -36 (-43 (-43,33) -36 (-43 (-43,33) -36	16 Total No. 2021 169747 20530 10401 88097 12017 5569 7722 953 798	6 Difference 2016/19 to 2021 -67807 -3705 -3054 -40291 -2352 -1933 -4043 -282 -144		→ 64 (4,19 200 200 2016/19/19/ 2016/19/19/ 2016/19/19/ 2016/19/19/ 2016/19/19/ 2016/19/19/ 2016/19/19/ 2016/10
dure for. /ales dure for. re Procedure codures ngland cotiand /ales re mgland cotiand /ales fre Failure resynchronis ngland cotiand /ales	10 Mean No. 2016/19 227554 24215 13455 128388 128388 14809 7502 11785 7502 11785 7502 11785 742 ation 56533 3523	6 <b>Total No. 2020</b> 162283 19105 9090 82479 11122 4802 7112 941 450 44719 3213	4 2014/19-to 2020 2014/19-to 2020 5130 4365 2030 4365 2450 2450 2450 2450 2450 2450 2450 245		-38 (74,45) 100 5 change (95% Cl) 2016(15 to 2020 -32 (38,25) -32 (38,25) -32 (38,25) -32 (38,26) -36 (-41,28) -36 (-41,28) -37 (-41	16 Total No. 2021 166747 20530 10401 88097 12017 5569 7722 953 598 44255 3383	6 Difference 2016/19 to 2021 - 67807 - 3705 - 3054 - 40291 - 21933 - 4043 - 3282 - 324 - 404 - 12278 - 140		→ 64 (4),9 200 200 301 2016/19 to 1 2016/19 to 1 2016
dure for. release dure for. re Procedures redures reland cotland rales re regland cotland rales respective respective respective reland cotland rales respective respective respective reland cotland rales respective respective respective reland cotland rales respective respective respective respective reland cotland rales respective respec	10 Mean No. 2016/19 2337554 24235 134555 128388 14369 7502 11765 1233 742 ation 565333	6 Total No. 2020 162283 19105 9090 82479 11122 4802 7172 941 450 44719	-4 180 2016/19 to 2020 -75271 5130 -3365 -3369 -3347 -2700 -4593 -294 -292 -292		-38 (74,45) 150 <b>% change (95% CI)</b> <b>2016/19 to 2020</b> -12 (132,25) -21 (122,26) -32 (138,25) -21 (23,26) -36 (43,28) -36 (43,28) -36 (43,28) -39 (44,28) -39 (44,28) -39 (44,28) -39 (44,28) -39 (48,26) -31 (25,26)	16 Total No. 2021 169747 20530 10401 88097 12017 12017 12017 12097 12017 12017 12097 10	6 Difference 2014/1940 2021 -67807 -07907 -07907 -07907 -0291 -0		→ 64 (4,19 200 200 3 change (9 2016/19 to) 20 (35, 2 20 (35, 2))))))))))
dure for. e Procedure cedures igland otland ales c ugland otland ales gland otland ales esynchronis gland otland ales respective sigland ales	10 Mean No. 2016/19 227554 24215 13455 128388 128388 14809 7502 11785 7502 11785 7502 11785 742 ation 56533 3523	6 Total No. 2020 162283 1905 9090 82479 11122 4802 7172 941 450 2497 2497 92	4 2014/19-to 2020 2014/19-to 2020 5130 4365 2030 4365 2450 2450 2450 2450 2450 2450 2450 245		-38 (74,45) 100 5 change (95% Cl) 2016(15 to 2020 -32 (38,25) -32 (38,25) -32 (38,25) -32 (38,26) -36 (-41,28) -36 (-41,28) -37 (-41	16 Total No. 2021 166747 20530 10401 88097 12017 5569 7722 953 598 44255 3383	6 Difference 2016/19 to 2021 - 67807 - 3705 - 3054 - 40291 - 21933 - 4043 - 3282 - 324 - 404 - 12278 - 140		→ 64 (4,0) 200 200 3 change (9) 2016/19 to 2016/19 to 2016/1
dure for. fales dure for. e Procedure coedure rgland cotland fales rallond cotland fales Fallure resynchronis rgland cotland fales Fallure respind cotland fales fal	10 Mean No. 2016/19 237554 24235 13455 128388 14369 7502 11765 7502 11765 762 742 ation 56533 3069	6 Total No. 2020 162283 19105 82479 11122 4802 7172 4802 7172 4802 7172 4802 7172 4802 7172 4802 7172 4802 7172 4802 7172 4802 7172 4802 7172 4802 7172 7172 7172 7172 7172 7172 7172 71	4 2016/19-10 2020 2016/19-10 2020 		-38 (74,45) -36 -37 -32 (38,25) -32 (38,25) -32 (38,25) -32 (38,26) -32 (38,26) -32 (34,21) -36 (41,28) -36 (41,21) -36 (41,21) -37 (41,	16 Total No. 2021 169747 20140 10401 5569 7722 7593 5598 44255 3383 2819	6 Difference 2016/19 to 2021 - 67807 - 3705 - 3705 - 47097 - 3705 - 3705 - 47097 - 3705 - 47097 - 3705 - 4709 -		→ 64 (4,9) 200 200 301 201 301 2016/19 to 1 2016/19 t
Jure for, The Tockure for The Tockure for Tockure	10 Mean No. 2016/19 237554 24215 128388 14309 7502 11765 12838 14309 7502 11765 1283 14309 100 12	6 Total No. 2020 162283 19105 9090 82479 11122 4802 7172 4802 7172 4802 7172 941 450 3213 2497 92 14	4 50 50 50 50 50 50 50 50 50 50 50 50 50		-38 (74,45) 100 5 schange (95% Cl) 2016(15 to 2020) -32 (-38, 25) -21 (-22, 20) -32 (-38, 25) -21 (-22, 20) -32 (-38, 20) -35 (-43, 20) -36 (-41, 32) -36 (-31, 42) -36 (-32, 42) -36 (-36) -36 (	16 Total No. 2021 169747 22530 10401 88097 12017 10017 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 1000000	6 Difference 2016/19 to 2021 -67807 -3705 -47907 -3705 -47907 -2551 -4032 -4032 -4		→ 64 (4,9) 200 200 301 201 301 2016/19 to 1 2016/19 t
Jure for. The Procedure cedures agland cedures agland cotland ales c gland c ales c agland c ales c ales c ales c ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c c diad d ales c diad d ales c diad d ales c diad d ales c diad d ales c diad d ales c diad d ales c diad d ales c diad d ales c diad d ales c diad d ales c diad d diad d ales c diad d d d d d d d d d d d d d	10 Mean No. 2016/19 237554 24215 128388 14309 7502 11765 12838 14309 7502 11765 1283 14309 100 12	6 Total No. 2020 162283 19105 9090 82479 11122 4802 7172 4802 7172 4802 7172 941 450 3213 2497 92 14	4 50 50 50 50 50 50 50 50 50 50 50 50 50		-38 (74,45) 150 <b>% change (95% C)</b> <b>2016/19 to 2020</b> -12 (122,20) -22 (138,250) -21 (122,20) -36 (43,22) -36 (43,22) -36 (43,22) -36 (43,22) -36 (43,22) -39 (44,23) -39 (44,23) -39 (44,23) -39 (44,24) -39 (42,25) -41 (54,29) -21 (25,50) -41 (54,29) -22 (42,50)	16 Total No. 2021 169747 22530 10401 88097 12017 10017 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 1000000	6 Difference 2016/19 to 2021 -67807 -3705 -47907 -3705 -47907 -2551 -4032 -4032 -4		→ 64 (8,19 200 200 2016/29 to: 2016/29 t
Jure for. a books a	10 Mean No. 2016/19 237554 24235 13455 128388 14809 7502 11785 762 11785 76331 3553 35533 35533 35533 35533 1009 100 12 rombactomy 36	6 Tetal No. 2020 162283 19105 50905 824799 11122 4802 7172 4802 7172 4802 7172 4803 7172 92 14 9 117	4 505 2016/19 to 2020 2016/19 to 2020 2010 2010 2010 2010 2010 2010 2010		-38 (74,45) -30 -30 -32 (-38, 25) -32 (-38, 25) -32 (-38, 25) -32 (-38, 25) -32 (-38, 25) -32 (-38, 25) -32 (-38, 28) -35 (-43, 28) -36 (-43, 28) -36 (-43, 28) -39 (-48, 28) -39 (-43, -48) -9 (-23, -58) -19	16 Total No. 2021 169747 22530 10401 5599 7222 5598 7223 5598 44255 3383 2819 90 6 1117	6 Difference 2016/19 to 2021 -07807 -0705 -0251 -025		→ 64 (8,19 200 200 2016/29 to: 2016/29 t
dure for. The Procedure Reformed and the second a	10 Masn No. 2014/19 237554 24235 11455 128388 14450 128388 14460 1553 1205 1205 1205 1205 1455 1205 1455 1205 1455 1205 1455 1205 1455 1553 1457 1455 1455 1455 1455 1455 1455 1455 1553 1457 1457 1553 1553 1553 1553 1553 1553 1553 105 155 1553 105 155 155 155 155 155 155 155	6 Tetal No. 2020 162283 19105 9090 82479 11122 4802 7172 4802 7172 4802 7172 4803 7172 92 14 9 117 15	4 Difference 2014/940 2020 -75777 5120 -45599 -3455 -45599 -3470 -3470 -5592 -4593 -3470 -572 -11814 -310 -572 -68 -3 -3 -81 -81 -81 -81 -81 -81 -81 -81		-38 (74,45) 10 30 30 (38,75) 21 (22,78) -32 (38,75) -32 (34,75) -32 (34,75) -36 (41,33) -36 (41,33) -37 (42,54) -36 (41,33) -37 (42,54) -37 (42,54) -37 (42,56) -37 (42,56)	16 Total No. 2011 169747 20530 10901 10901 10901 10901 10901 10901 10901 10901 10901 10901 10901 10901 10901 10901 10901 10904 10	5 Difference 2014/94-0 2021 		→ 64 (4,19) 200 201 30 2016/19 to 1 2016/19 to 1 2016
dure for. The Procedure recedures recedur	10 Maan No. 2016/19 237554 24235 128388 14.807 7502 11235 702 11235 702 11235 702 11235 702 11235 1069 100 12 rommachan 36 0	6 Tetal No. 2020 162283 19105 50905 824799 11122 4802 7172 4802 7172 4802 7172 4803 7172 92 14 9 117	4 505 2016/19 to 2020 2016/19 to 2020 2010 2010 2010 2010 2010 2010 2010		-38 (74,45) 150 <b>% change (95% C)</b> <b>2016/19 to 2020</b> -12 (122,20) -22 (138,250) -21 (122,20) -36 (43,22) -36 (43,22) -36 (43,22) -36 (43,22) -36 (43,22) -39 (44,23) -39 (44,23) -39 (44,23) -39 (44,24) -39 (42,25) -41 (54,29) -21 (25,50) -41 (54,29) -22 (42,50)	16 Total No. 2021 169747 22530 10401 5599 7222 5598 7223 5598 44255 3383 2819 90 6 1117	6 Difference 2016/19 to 2021 -07807 -0705 -0251 -025		→ 64 (4,99 200 200 201 200 3 change (55 2016/19 to ) 2016/19 to ) 201
ture for	10 Maan No. 2016/19 237554 24215 128388 14309 7502 11265 1223 742 11255 56333 5059 160 12 rommor stanting 2567 359 142	6 Total No. 2020 162283 19105 82479 11122 4802 7172 941 450 4479 941 450 450 450 12723 941 92 117 15 1798	4 107 107 107 108 109 109 109 109 109 109 109 109		-38 (74,45) 100 500 500 500 500 500 500 500	16 Total No. 2021 169747 20530 12017 5508 7722 953 5508 40255 3383 2819 90 6 1117 10 2051	6 Difference 2016/19 to 2021 -67807 -3705 -40291 -2253 -1933 -40291 -2253 -2254 -2255 -2254 -2255 -2254 -2255 -2254 -2255 -2254 -2255 -2254 -2255 -2254 -2255 -2254 -2255 -2254 -2255 -25		→ 64 (4,19 200 200 9 schange (9 2014)(9 to) - 20 (35, 2 - 21 (20) - 20 (35, 2 - 31 (39,
hure for. The Procedure cedures gland otiand ales otiand ales otiand ales otiand ales otiand ales otiand ales otiand ales otiand ales otiand ales otiand otiand ales otiand otiand ales otiand otiand ales otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand ales otiand otiand ales otiand otiand ales otiand otiand ales otiand otiand ales otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand otiand ales otiand otian	10 Maan No. 2016/19 237554 24215 128388 14309 7502 11265 1223 742 11255 56333 5059 160 12 rommor stanting 2567 359 142	6 <b>Total No. 2020</b> 162283 19050 824479 11122 4802 7172 941 4503 2497 921 2497 921 107 107 107 107 107 107 107 10	4 Difference 2014/940 2020 -75777 5120 -45599 -3470 -4599 -3470 -4593 -349 -4593 -349 -4593 -349 -4593 -349 -4593 -349 -31 -31 -31 -31 -31 -31 -31 -31		-38 (74,45) 10 50 50 50 50 50 50 50 50 50 5	16 Total No. 2011 169747 20530 10901 10901 10901 10901 10901 10901 10901 10901 1091	6 Difference 2016/19 to 2021 - 67807 - 3705 - 3005 - 40291 - 2252 - 1933 - 40291 - 2252 - 1933 - 40291 - 2252 - 2		→ 64 (4,19) 200 201 2014(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)(
ture for. The Fockburg show of the fockbur	10 Mean No. 2014/19 233554 24215 128388 14400 128388 14407 7502 128388 14407 7502 1255 1075 1	6 Total No. 2020 163283 19050 82479 11122 4802 7272 941 4573 2497 94 44719 941 4573 2497 92 117 15 1788 246 74 732 131	4 107 107 107 107 107 107 107 107		-38 (74,45) 10 50 50 50 50 50 50 50 50 50 5	16 Total No. 2011 169747 10001 10001 10007 10007 10007 10007 10007 10007 1000 1000 10007 1000 1000 10007 1000 10007 1000 10007 1	6 Difference 2016/19 to 2021 		→ 64 (4,19) 200 201 2014(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)(2)(
dure for, tales dure for, for Procedures ugland tales ugland otian algand otian algand otian algand otian algand otian algand otian dure for, bland otian algand otian dure for, bland otian algand otian dure for, bland otian dure for, bland otian dure for, bland otian dure for, bland otian dure for, bland otian dure for, bland otian dure for, bland dure for, dure for, du	10 Maan No. 2016/19 237554 24215 128388 14389 7502 11265 1223 762 11255 762 11255 762 11255 762 11255 762 11255 763 765 12838 160 12 765 128 765 12838 160 12 765 128 765 12838 160 160 12 765 160 160 160 160 160 160 160 160	6 Total No. 2020 162283 19105 82479 11122 4802 7122 941 450 44719 2433 2497 92 14 9 1117 15 1798 246 74 732	4 107 107 107 107 107 107 107 107		-38 (74,45) 100 500 500 500 500 500 500 500	16 Total No. 2021 169747 20530 12017 5569 7722 5569 7723 5569 2027 793 5569 2027 2023 2029 2020 2020 2020 2020 2020 2020	6 Difference 2016/19 to 2021 - 67807 - 3705 - 3005 - 40291 - 2252 - 1933 - 40291 - 2252 - 1933 - 40291 - 2252 - 2		→ 64 (4,194 200 200 200
dure for. In Procedures refronted to the second refronted to the sec	10 Maan No. 2016/19 237554 24215 128388 128388 128388 128388 12255 742 11765 1225 742 11765 1225 742 11765 1225 742 11765 1225 742 12754 128388 11255 128388 11255 128388 11255 128388 128388 1285 128388 1285 128388 1285 1285 1285 128388 1285 1895 1805 180 180 195 1805 195 1805 195 1805 195 1805 195 1805 195 195 195 195 195 195 195 19	6 Total No. 2020 162283 19105 82479 11122 4802 7172 941 450 44719 3213 32497 92 14 9 117 15 1788 246 74 752 131 60	4 107 107 107 107 107 107 107 107		-36 (24,45) 120 20 20 (45,26) 20 (25,26) 20 (25,2	16 Total No. 2011 169747 10001 10001 10007 10007 10007 10007 10007 10007 1000 1000 10007 1000 1000 10007 1000 10007 1000 10007 1	6 Difference 2016/19 to 2021 - 67807 - 3705 - 40291 - 40291 - 2352 - 1933 - 40291 - 2352 - 2		→ 66 ( ₹1,94 200 200 200 2016/19 to 2 2016/19 to 2 2017051 2017051 2017051 2017051 2017051 2017051
Aure for. In Procedore gland gland uglan	10 Mean No. 2016/19 237554 24215 128388 128388 128388 128388 128388 1285 742 3523 3523 3523 3523 3533 3529 100 12 remeded only 100 12 remeded only 140 12 12 12 12 12 12 12 12 12 12	6 Total No. 2020 162283 19105 82479 11122 4802 7112 941 450 44719 32489 2489 92 14 9 1117 15 1798 246 732 131 60 6051 850	4 2016		-38 (74,45) 120 210 2116(1510 2020 -21 (42,20) -21 (42,20) -21 (42,20) -21 (42,20) -21 (42,20) -36 (43,20) -36 (43,20) -39 (44,20) -39 (44,20) -39 (44,20) -39 (44,20) -39 (44,20) -39 (44,20) -39 (43,20) -9 (52,50) -21 (42,50) -21 (42,50) -21 (42,50) -21 (42,50) -21 (42,50) -21 (42,50) -21 (42,50) -21 (42,50) -20 (75,519) -30 (34,30) -30 (34,30) -30 (34,30) -30 (34,30) -30 (34,30) -30 (34,30) -30 (34,20) -30 (34,20) -30 (34,20) -30 (34,20) -30 (34,20) -30 (37,20) -30 (	16 Total No. 2021 169747 20530 12017 5569 7222 793 558 44255 32819 90 6 1117 2051 282 2829 90 6 1117 282 283 2819 90 6	6 Difference 2016/19 to 2021 - 67807 - 3705 - 3055 - 40391 - 2352 - 1933 - 40391 - 2352 - 1933 - 40391 - 2352 - 3055 - 3		→         66 (₹1,9)           200         200           3         change (5)           2016/19 to 1         2016/19 to 1           -2016/19 to 1         -2016/19 to 1           -2017/10 to 1         -2016/19 to 1
dure for. In Froedore gland data ugland data ugland tales ugland tales ugland tales ugland tales tal	10 Maan No. 2016/19 237554 24215 128388 14360 15533 11785 12375 123754 1460 7502 123754 1460 7502 123754 1450 11785 12375 100 12 100 12 100 12 100 12 100 12 100 12 100 100	6 Total No. 2020 162283 19105 11122 4800 44719 941 4550 44719 941 4550 44719 941 947 941 15 1786 748 748 748 749 747 75 758 748 748 748 748 748 748 748 74	4 100 100 100 100 100 100 100 10		-38 (74,45) 10 50 50 50 50 50 50 50 50 50 5	16 Total No. 2021 160747 20530 12017 12017 12017 12017 12017 12037 10	6 Difference 2016/19 to 2021 - 67807 - 3705 - 3705 - 40091 - 2553 - 3705 - 4043 - 742 - 4043 - 742 - 4043 - 742 - 740 - 70 - 6 - 81 - 10 - 70 - 6 - 81 - 10 - 70 - 70 - 6 - 81 - 10 - 70 - 70 - 70 - 6 - 81 - 10 - 70 - 81 - 10 - 70 - 70 - 70 - 81 - 10 - 70 - 70		→         66 (₹1,9)           200         200           3         change (5)           2016/19 to 1         2016/19 to 1           -2016/19 to 1         -2016/19 to 1           -2017/10 to 1         -2016/19 to 1
dure for. The Procedure of Procedure of P	10 Maan No. 2014/19 213754 24215 128388 14800 7502 128388 14800 7502 128388 14800 7502 100 12 100 12 100 12 100 12 100 12 100 12 100 12 100 12 100 12 100 12 100 100	6 Total No. 2020 162283 19105 82479 11122 4800 44719 941 450 44719 941 450 44719 941 450 1177 15 1798 246 74 712 1177 15 1798 246 74 712 1177 15 1798 246 74 712 1177 1178 117	4 100 100 100 100 100 100 100 10		-38 (24,45) 10 30 30 30 30 30 30 30 30 30 3	16 Total No. 2021 160747 20530 12017 5568 4255 3283 2819 90 6 117 10 2051 282 533 2819 90 6 117 10 2055 282 155 82 10 10 10 10 10 10 10 10 10 10	6 Difference 2016/19 to 2021 - 47807 - 3705 - 40991 - 2553 - 40991 - 2553 - 40991 - 2553 - 4091 - 4		→ 64(4)39 200 200 301 200 301 2016/19/90 2 2016/19/90
dure for. A frocador of rocador of roca	10 Mean No. 2016/19 237554 24215 128388 128388 128388 128388 128388 1285 742 3523 3523 3523 3523 3533 3529 100 12 remeded only 100 12 remeded only 140 12 12 12 12 12 12 12 12 12 12	6 Total No. 2020 162283 19105 82479 11122 4802 7112 941 450 44719 32489 2489 92 14 9 1117 15 1798 246 732 131 60 6051 850	4 2016		-38 (74,45) 120 210 2116(1510 2020 -21 (42,20) -21 (42,20) -21 (42,20) -21 (42,20) -21 (42,20) -36 (43,20) -36 (43,20) -39 (44,20) -39 (44,20) -39 (44,20) -39 (44,20) -39 (44,20) -39 (44,20) -39 (43,20) -9 (52,50) -21 (42,50) -21 (42,50) -21 (42,50) -21 (42,50) -21 (42,50) -21 (42,50) -21 (42,50) -21 (42,50) -20 (75,519) -30 (34,30) -30 (34,30) -30 (34,30) -30 (34,30) -30 (34,30) -30 (34,30) -30 (34,20) -30 (34,20) -30 (34,20) -30 (34,20) -30 (34,20) -30 (37,20) -30 (	16 Total No. 2021 169747 20530 12017 5569 7222 793 558 44255 32819 90 6 1117 2051 282 2829 90 6 1117 282 283 2819 90 6	6 Difference 2016/19 to 2021 - 67807 - 3705 - 3055 - 40391 - 2352 - 1933 - 40391 - 2352 - 1933 - 40391 - 2352 - 3055 - 3		→         66 (4,194)           200         200           30 and the set of the set
dure for. A freedown for Freedown gland falses ugland falses talses	10 Maan No. 2016/19 237554 2425 128388 14450 128388 14450 128388 14450 128388 1455 1205	6 Total No. 2020 162283 19105 82479 11122 4802 7172 941 450 44719 3213 2489 7473 749 1249 117 15 1798 246 749 742 131 60 60 51 363 363 363 363 11898 11898 11898	4 107 107 107 107 107 107 107 107		-38 (74,45) 120 210 2116(151 to 2020 -22 (43,25) -21 (42,20) -21 (42,20) -21 (42,20) -21 (43,20) -21 (43,20) -21 (43,20) -36 (43,20) -36 (43,20) -39 (43,20) -21 (25,16) -39 (43,20) -21 (25,16) -39 (43,20) -21 (25,16) -39 (43,20) -21 (25,16) -21 (25,16) -39 (43,20) -21 (42,20) -21 (42,20) -21 (42,20) -39 (37,21) -39 (37,22) -39 (37,22) -39 (43,20) -17 (43,20) -39 (43,20) -17 (43,20) -39 (43,20) -17 (43,20) -39 (43,20) -17 (43,20) -39 (43,20) -17 (43,20) -39 (43,20) -17	16 Total No. 2021 169747 22530 10007 12017 5569 7222 733 358 44255 32819 90 6 1117 90 6 1117 282 3283 2819 90 6 1117 282 3283 2819 90 6	6 Difference 2016/39 to 2021 - 67807 - 3705 - 3055 - 40391 - 2352 - 2352 - 2352 - 2352 - 2484 - 2355 - 2484 - 2498 - 249		→ 66 (4),99 200 200 300 200 301,079 to 2 301,079 to 2
dure for. A loss of the second secon	10 Maan No. 2014/19 237554 2425 128388 14450 128388 14450 128388 14450 128388 1455 1205 1005 100 12 10 10 10 10 10 10 10 10 10 10	6 Total No. 2020 162283 19050 824479 11122 4802 7172 941 4530 44739 3213 2489 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 71	4 Difference 2014/940 2020 		-38 (74,45) 10 50 50 50 50 50 50 50 50 50 5	16 Total No. 2011 169747 2033 10901 10901 10901 10901 10901 10901 10901 10901 1090	6 Difference 2014/94 to 2021 		→ 64 (4,194 200 200 200 30 430,2 30 440,2 31 430,2 34 440,2 34 440,2
dure for. A loss of the second of the secon	10 Maan No. 2016/19 2137554 24235 123388 14360 7500 12333 100 12 rombactomy 100 12 rombactomy 100 12 2567 399 142 155 142 165 168 13 168 13 168 13 168 168 168 168 168 168 168 168	6 Total No. 2020 162283 19105 82479 11122 4800 7722 941 450 44719 94 450 44719 94 450 44719 94 450 44719 92 117 158 106 6051 850 308 11898 118	4 187 197 197 197 197 197 197 197 19		-38 (74,45) 10 50 50 50 50 50 50 50 50 50 5	16 Total No. 2021 169747 20530 20530 7722 953 2053 2053 2053 2054 2051 2051 2051 2053 2054 2055 2054 2055 2054 2055 2054 2055 2	6 Difference 2016/19 to 2021 - 47807 - 3705 - 40291 - 2153 - 2153 - 2153 - 2153 - 2153 - 2153 - 2153 - 2153 - 215 - 215		→         64 (4) 34           200         200           3016/19 to 2         200           3016/19 to 2         2016/19 to 2           3016/10 to 2         3016/10 to 2           3016/10 t
dure for. A vives for. A recedence of the second of the	10 Maan No. 2014/19 237554 2425 128388 14450 128388 14450 128388 14450 128388 1455 1205 1005 100 12 10 10 10 10 10 10 10 10 10 10	6 Total No. 2020 162283 19050 824479 11122 4802 7172 941 4530 44739 3213 2489 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 450 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 941 7172 71	4 Difference 2014/940 2020 		-38 (74,45) 10 50 50 50 50 50 50 50 50 50 5	16 Total No. 2011 169747 2033 10901 10901 10901 10901 10901 10901 10901 10901 1090	6 Difference 2014/94 to 2021 		64 (-8,194
dure for. A loss of the second of the secon	10 Mean No. 2014/19 237554 24235 128388 14460 128388 14460 128388 14460 128388 14460 12952 1005 10059 1059 1816 608	6 Total No. 2020 162283 19105 82479 11122 4800 7722 941 450 44719 94 450 44719 94 450 44719 94 450 44719 92 117 158 106 6051 106 850 308 11898 106 11898	4 2014/1940 2024 19507 1950		-36 (24,45) 20 50 50 50 50 50 50 50 50 50 5	16 Total No. 2021 169747 20530 20530 7722 953 2053 2053 2053 2054 2051 2051 2051 2053 2054 2055 2054 2055 2054 2055 2054 2055 2	6 Difference 2014(19 to 2021) 		→         64 (4,3)9           200         200           301 (3), 2         201 (3), 2           301 (3), 2         201 (3), 2           301 (3), 2         201 (3), 2           301 (3), 2         201 (3), 2           301 (3), 2         201 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 2         301 (3), 2           301 (3), 3         301 (3), 2           301 (3), 3         301 (3), 2           301 (3), 3
vare for. Procedures gland gland ales ales gland ales	10 Maan No. 2016/19 2137554 24235 123388 14360 7500 12333 100 12 rombactomy 100 12 rombactomy 100 12 2567 399 142 155 142 165 168 13 168 13 168 13 168 168 168 168 168 168 168 168	6 Total No. 2020 150283 19050 82479 11122 941 4503 44719 941 4573 2469 117 15 1786 246 717 246 717 246 717 246 717 15 1786 6051 850 6051 850 1189 1199 119	4 187 197 197 197 197 197 197 197 19		-38 (74,45) 10 50 50 50 50 50 50 50 50 50 5	16 Total No. 2011 169747 20530 10001 10001 10001 10001 10001 10001 10001 1000 10001 100000 100000 100000 100000 100000 100000 100000000	6 Difference 2016/19 to 2021 - 47807 - 3705 - 40291 - 2153 - 2153 - 2153 - 2153 - 2153 - 2153 - 2153 - 2153 - 215 - 215		→         66 (4) (3)           200         200           30         2016/19/19           2016/19/19

Figure 6. Annual counts and percentage change in total emergency and elective procedures between pre-pandemic (2016–19) and pandemic (2020–21) periods for all cardiovascular procedures and across subtypes and across three countries in the UK.

### Strengths/limitations

Our analyses used standardised, validated, open-source coding in national level EHR data in the most comprehensive investigation of indirect effects to-date. We used pre-pandemic data for comparison. We used the same methods for admissions and procedures across diseases, CVD subtypes and comparable datasets across countries.<sup>17</sup> Our study does have some limitations. First, we only investigated some, not all CVD admissions and procedure. Second, there were low numbers for certain procedures, particularly in Scotland and Wales. Third, we only examined inpatient and not outpatient or emergency department activity. Fourth, we only had socio-demographic and comorbidity data at baseline and not tracked over time. Fifth, we do not look in detail at impact of lockdowns, vaccination, and successive waves. Sixth, we are reliant on EHR and coding errors are possible though prior published studies suggest that this is unlikely to be a major issue. Seventh, we did not investigate impact of changes in CVD admissions or procedures on CVD-related mortality, which should be considered in future studies. Eighth, using these data and analyses, we could not conclude whether observed changes were due to patient-driven (e.g. fear of hospital attendance), staff shortage (e.g. redeployment, sickness), or hospital policy (e.g. cancelation of elective procedures), which will require further research. Finally, our analyses only concerned UK healthcare system and data, and may not be necessarily generalisable to other countries and settings.

# Implications for clinical practice and policy

Our results suggest that procedural activity needs to be prioritised and planned to provide timely services for high-risk patients during pandemics. Data about potential indirect effects needs to be collected and monitored, and ways of collecting, storing, and analysing data need to be standardised across diseases and procedures, i.e. we cannot have every specialty and disease developing its own methods and 'reinventing the wheel'. During planning for pandemics, NCD surveillance needs to be a part of the preparation and during pandemics, it should be a part of the dashboards.

# Implications for research

With the advent of national TRE data, the type of research which we have conducted needs to be scaled up. Open-source data and methods can facilitate valid comparisons within and across countries, but differences in capture and coding of data need to be taken into account. Our methods and our results have application to other diseases<sup>19,20</sup> and other countries, with potential implications for current and future pandemic policy. The science of pandemic preparedness has been largely restricted to infection dynamics. Future prediction models have to incorporate NCDs, and should include indirect effects, which may be as profound as direct effects.

# Conclusions

There have been wide and far-reaching reductions in secondary care for CVD throughout the pandemic, with incomplete recovery, particularly for procedural and elective activity, even 2 years into the COVID-19 pandemic. Monitoring and protection of cardiovascular and non-COVID services should be part of pandemic planning in future.

# Supplementary material

Supplementary material is available at European Heart Journal—Quality of Care and Clinical Outcomes online.

# Acknowledgment

This work is carried out with the support of the BHF Data Science Centre led by HDR UK (BHF Grant no. SP/19/3/34678). This study makes use of de-identified data held in NHS Digital's TRE for England, the SAIL Databank and the Scottish National Data Safe Haven and made available via the BHF Data Science Centre's CVD-COVID-UK/COVID-IMPACT consortium. This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make health relevant data available for research.

The study makes use of anonymised data held in the Scottish National Safe Haven. The authors would like to acknowledge the support of the eDRIS Team (Public Health Scotland) for their involvement in obtaining approvals, provisioning and linking data and the use of the secure analytical platform within the National Safe Haven.

This study makes use of anonymised data held in the SAIL Databank. This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make anonymised data available for research. We wish to acknowledge the collaborative partnership that enabled acquisition and access to the de-identified data, which led to this output. The collaboration was led by the Swansea University Health Data Research UK team under the direction of the Welsh Government Technical Advisory Cell (TAC) and includes the following groups and organisations: the SAIL Databank, Administrative Data Research (ADR) Wales, Digital Health and Care Wales (DHCW), Public Health Wales, NHS Shared Services Partnership (NWSSP) and the Welsh Ambulance Service Trust (WAST). All research conducted has been completed under the permission and approval of the SAIL independent Information Governance Review Panel (IGRP) project number 0911.

The Big Data Institute has received funding from the Li Ka Shing Foundation and Robertson Foundations, the Medical Research Council, British Heart Foundation, and is supported by the NIHR Oxford Biomedical Research Centre.

# Funding

The British Heart Foundation Data Science Centre (grant No SP/19/3/34 678, awarded to Health Data Research (HDR) UK) funded co-development (with NHS Digital) of the TRE, provision of linked datasets, data access, user software licences, computational usage, and data management and wrangling support with additional contributions from the HDR UK Data and Connectivity component of the UK Government Chief Scientific Adviser's National Core Studies programme to coordinate national covid-19 priority research. Consortium partner organisations funded the time of contributing data analysts, biostatisticians, epidemiologists, and clinicians. This work was supported by the Con-COV team funded by the Medical Research Council (grant number: MR/V028367/1).

This work was supported by Health Data Research UK, which receives its funding from HDR UK Ltd (HDR-9006) funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation (BHF) and the Wellcome Trust.

This work was supported by the ADR Wales programme of work, aligned to the priority themes 410 as identified in the Welsh Government's national strategy: Prosperity for All. ADR Wales brings together data science experts at Swansea University Medical School, staff from the Wales Institute of Social and Economic Research, Data and Methods (WISERD) at Cardiff University and specialist teams within the Welsh Government to develop new evidence which supports Prosperity for All by using the SAIL Databank at Swansea University, to link and analyse anonymised data. ADR Wales is part of the Economic and Social Research Council (part of UK Research and Innovation) funded ADR UK (grant ES/S007393/1). This work was supported by the Wales COVID-19 Evidence Centre, funded by Health and Care Research Wales.

# **Conflict of interest**

A.B. has received research grants from National Institute for Health and Care Research (NIHR), British Medical Association, UK Research and Innovation, European Union, and AstraZeneca. A.B. is trustee of the South Asian Health Foundation and Long COVID SOS. Other authors have declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

# Authors' contributions

A.B., F.L.W., and E.M. conceptualised the study. F.L.W. and A.B. were the project leads. F.L.W. and A.B. created the data specifications. N.Hall, K.C., D.O'C., Z.K., and D.M-M. were responsible for data extraction. N.I., K.C., D.O'C., D. M-M., and R.G. conducted data analyses. R.G. and E.S. provided statistical advice. F.L.W., E.M., B.L., R.G., and A.B. reviewed the methods and interpreted the data. K.C., N.Herz and N.I. produced the graphics. C.S. is the Director of the BHF Data Science Centre and coordinated approvals for and access to data within NHS Digital's TRE for England, the SAIL Databank and the Scottish National Safe Haven for CVD-COVID-UK/COVID-IMPACT. F.L.W. and A.B. drafted the manuscript and all authors reviewed and edited the final version of the manuscript.

## Ethics

The North East—Newcastle and North Tyneside 2 research ethics committee provided ethical approval for the CVD-COVID-UK/COVID-IMPACT research programme (REC No 20/NE/0161) to access, within secure trusted research environments, unconsented, whole-population, de-identified data from electronic health records collected as part of patients' routine healthcare.

### Data availability

The data used in this study are available in NHS Digital's TRE for England, but as restrictions apply they are not publicly available (https://digital.nhs.uk/coronavirus/coronavirus-data-services-updates/ trusted-research-environment-service-for-england). The CVD-COVID-UK/COVID-IMPACT programme led by the BHF Data Science Centre (https://www.hdruk.ac.uk/helping-with-health-data/ bhf-data-science-centre/) received approval to access data in NHS Digital's TRE for England from the Independent Group Advising on the Release of Data (IGARD) (https://digital.nhs. uk/about-nhs-digital/corporate-information-and-documents/

independent-group-advising-on-the-release-of-data) via an application made in the Data Access Request Service (DARS) Online system (ref. DARS-NIC-381078-Y9C5K) (https://digital.nhs.uk/services/ data-access-request-service-dars/dars-products-and-services).

The CVD-COVID-UK/COVID-IMPACT Approvals & Oversight Board (https://www.hdruk.ac.uk/projects/cvd-covid-uk-project/) subsequently granted approval to this project to access the data within NHS Digital's TRE for England, the Scottish National Safe Haven and the SAIL Databank. The de-identified data used in this study were made available to accredited researchers only. Those wishing to gain access to the data should contact bhfdsc@hdruk.ac.uk in the first instance. Data used in this study are available in the Scottish National Safe Haven (Project Number: 2021–0102), but as restrictions apply they are not publicly available. Access to data may be granted on application to, and subject to approval by, the Public Benefit and Privacy Panel for Health and Social Care (PBPP (https://www.informationgovernance.scot.nhs.uk/pbpphsc/)). Applications are coordinated by eDRIS (electronic Data Research and Innovation Service (https://www.isdscotland.org/ Products-and-services/Edris/)). The anonymised data used in this study was made available to accredited researchers only through the Public Health Scotland (PHS) eDRIS User Agreement (https://www.isdscotland.org/Products-and-services/Edris/\_docs/ eDRIS-User-Agreement-v16.pdf).

The data used in this study are available in the SAIL Databank at Swansea University, Swansea, UK, but as restrictions apply they are not publicly available. All proposals to use SAIL data are subject to review by an independent Information Governance Review Panel (IGRP). Before any data can be accessed, approval must be given by the IGRP. The IGRP gives careful consideration to each project to ensure proper and appropriate use of SAIL data. When access has been granted, it is gained through a privacy protecting safe haven and remote access system referred to as the SAIL Gateway. SAIL has established an application process to be followed by anyone who would like to access data via SAIL at https://www.saildatabank.com/ application-process

## References

- Banerjee A, Pasea L, Harris S, Gonzalez-Izquierdo A, Torralbo A, Shallcross L et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. Lancet North Am Ed. 2020;395:1715–1725.
- Ball S, Banerjee A, Berry C, Boyle JR, Bray B, Bradlow W et al. Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK. *Heart*. 2020;**106**:1890–1897.
- Banerjee A, Chen S, Pasea L, Lai AG, Katsoulis M, Denaxas S et al. Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. Eur J Prev Cardiol. 2021;28:1599–1609.
- 4. Lai AG, Pasea L, Banerjee A, Hall G, Denaxas S, Chang WH et al. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open. 2020;10:e043828.
- Ho KMA, Banerjee A, Lawler M, Rutter MD, Lovat LB. Predicting endoscopic activity recovery in England after COVID-19: a national analysis. *Lancet Gastroenterol Hepatol.* 2021;6:381–390.
- Islam N, Shkolnikov VM, Acosta RJ, Klimkin I, Kawachi I, Irizarry RA et al. Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries. BMJ. 2021;373: n1137.
- Martin GP, Curzen N, Goodwin AT, Nolan J, Balacumaraswami L, Ludman PF et al. Indirect impact of the COVID-19 pandemic on activity and outcomes of transcatheter and surgical treatment of aortic stenosis in England. *Circ Cardiovasc Interv.* 2021;14:e010413.
- Horton R. Offline: COVID-19 is not a pandemic. Lancet North Am Ed. 2020;396: 874.
- Mizani MA, Dashtban A, Pasea L, Lai AG, Thygesen J, Tomlinson C et al. CVD-COVID-UK Consortium. Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19-a data-driven retrospective cohort study. J R Soc Med. 2022. doi:10.1177/01410768221131897
- Vos T, Allen C, Arora M, Barber RM, Brown A, Carter A et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet North Am Ed. 2016;388:1545–1602.
- Guarinello GG, D'Amico RC, Miranda ANM, Novack J, Coral FE. Impacto da COVID-19 no perfil cirúrgico dos pacientes de cirurgia vascular em serviço de referência em Curitiba. J Vasc Bras. 2022;21:e20220027.
- Lechner I, Reindl M, Tiller C, Holzknecht M, Troger F, Fink P et al. Impact of COVID-19 pandemic restrictions on ST-elevation myocardial infarction: a cardiac magnetic resonance imaging study. Eur Heart J. 2022;43:1141–1153.

- Shoaib A, van Spall HGC, Wu J, Cleland JGF, McDonagh TA, Rashid M et al. Substantial decline in hospital admissions for heart failure accompanied by increased community mortality during COVID-19 pandemic. Eur Heart J Qual Care Clin Outcomes. 2021;7:378–387.
- Denaxas S, Gonzalez-Izquierdo A, Direk K, Fitzpatrick NK, Fatemifar G, Banerjee A et al. UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER. J Am Med Inform Assoc. 2019;26:1545–1559.
- Thygesen JH, Tomlinson C, Hollings S, Mizani MA, Handy A, Akbari A et al. COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records. The Lancet Digital Health. 2022;4:e542–e557.
- Wood A, Denholm R, Hollings S, Cooper J, Ip S, Walker V et al. Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: data resource. *BMJ*. 2021;373:n826.
- ISD Scotland. SMR Datasets. https://www.ndc.scot.nhs.uk/Data-Dictionary/SMR-Datasets/SMR01-General-Acute-Inpatient-and-Day-Case/ (Accessed 10/10/2022)
- Jones KH, Ford DV, Jones C, Dsilva R, Thompson S, Brooks CJ et al. A case study of the Secure Anonymous Information Linkage (SAIL) Gateway: a privacy protecting remote access system for health related research and evaluation. J Biomed Inform. 2014;50:196–204.
- Szakmany T, Hollinghurst J, Pugh R et al. Frailty assessed by administrative tools and mortality in patients with pneumonia admitted to the hospital and ICU in Wales. Sci Rep. 2021;11:13407.
- Banerjee A, Chen S, Pasea L et al. Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. Eur J Prev Cardiol. 2021;28:1599–1609.
- Banerjee A, Sudlow C, Lawler M. Indirect effects of the pandemic: highlighting the need for data-driven policy and preparedness. J R Soc Med. 2022;115:249–251.
- Grimm F, Johansen A, Knight H, Brine R, Deeny SR. Indirect effect of the COVID-19 pandemic on hospital mortality in patients with hip fracture: a competing risk survival analysis using linked administrative data. *BMJ Qual Saf.* 2022. doi:10.1136/bmjqs-2022-014896.
- UK Government. Department of Health and Social Care. Direct and indirect health impacts of COVID-19 in England: emerging Omicron impacts. 4 August 2022.

https://www.gov.uk/government/publications/direct-and-indirect-health-impacts-of-covid-19-in-england-emerging-omicron-impacts/direct-and-indirect-health-impacts-of-covid-19-in-england-emerging-omicron-impacts

- Friebel R, Fistein J, Maynou L, Anderson M. Emergency contracting and the delivery of elective care services across the English National Health Service and independent sector during COVID-19: a descriptive analysis. *BMJ Open.* 2022;**12**:e055875.
- McLellan A, Abbasi K. The NHS is not living with Covid, it's dying from it. BMJ. 2022;378:o1779.
- 26. van Ginneken E, Reed S, Siciliani L, Eriksen A, Schlepper L, Tille F et al. European Observatory on Health Systems and Policies. Addressing backlogs and managing waiting lists during and beyond the COVID-19 pandemic. *Policy Brief*. 2022;47. https://www. who.int/europe/news/item/20-07-2022-covid-19-has-caused-major-disruptionsand-backlogs-in-health-care-new-who-study-finds
- McCabe R, Schmit N, Christen P, D'Aeth JC, Løchen A, Rizmie D et al. Adapting hospital capacity to meet changing demands during the COVID-19 pandemic. BMC Med. 2020;18:329.
- Nehme R, Puchkova A, Parlikad A. A predictive model for the post-pandemic delay in elective treatment. Oper Res Health Care. 2022;34:100357.
- Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;**70**:1–25. doi: 10.1016/j.jacc.2017.04.052. Epub 2017 May 17.
- National Institute for Cardiovascular Outcomes Research (NICOR). NICOR COVID-19 Report. Rapid cardiovascular data: we need it now (and in the future). 2021. https: //www.nicor.org.uk/covid-19-and-nicor/nicor-covid-19-report/
- 31. UK Government. Abdominal aortic aneurysm screening: standards report 2019 to 2020. Data report for abdominal aortic aneurysm screening for 1 April 2019 to 31 March 2020. 25 Feb 2021. https://www.gov.uk/government/statistics/ abdominal-aortic-aneurysm-screening-standards-report-2019-to-2020
- Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S et al. Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales. *Circulation*. 2022;**146**:892–906.